NeurogesX Receives Notice of Two U.S. Patent Allowances Covering NGX-1998

NeurogesX, Inc. NGSX today announced it has received two notices of allowance from the United States Patent and Trademark Office (USPTO) for patents covering NGX-1998, the Company's next generation liquid formulation of prescription strength capsaicin. The first notice of allowance expands on NeurogesX' current patent entitled, "Methods and Compositions for Administration of TRPV1 Agonists," and includes claims that more specifically define the components of the liquid formulation of NGX-1998. The patent issuing from this application will have a term that expires in 2024. The second notice of allowance is for the Company's patent entitled, "Compositions and Kits for the Removal of Irritating Compounds from Bodily Surfaces." This allowance includes claims relating to methods for removing capsaicin from the body using a surfactant-free, polyethylene glycol gel, and is complementary to the NGX-1998 patent family. The patent issuing from this application will have a term that expires in 2022.